HUE057799T2 - EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció - Google Patents
EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombinációInfo
- Publication number
- HUE057799T2 HUE057799T2 HUE17824314A HUE17824314A HUE057799T2 HU E057799 T2 HUE057799 T2 HU E057799T2 HU E17824314 A HUE17824314 A HU E17824314A HU E17824314 A HUE17824314 A HU E17824314A HU E057799 T2 HUE057799 T2 HU E057799T2
- Authority
- HU
- Hungary
- Prior art keywords
- antagonist
- combination
- immune checkpoint
- checkpoint inhibitor
- inhibitor
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359504P | 2016-07-07 | 2016-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057799T2 true HUE057799T2 (hu) | 2022-06-28 |
Family
ID=60912958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17824314A HUE057799T2 (hu) | 2016-07-07 | 2017-07-06 | EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11065226B2 (hu) |
| EP (1) | EP3482760B1 (hu) |
| JP (2) | JP6323629B1 (hu) |
| KR (1) | KR102473601B1 (hu) |
| CN (1) | CN109475520B (hu) |
| AU (1) | AU2017292522B2 (hu) |
| CA (1) | CA3029611A1 (hu) |
| DK (1) | DK3482760T3 (hu) |
| ES (1) | ES2900306T3 (hu) |
| HU (1) | HUE057799T2 (hu) |
| IL (1) | IL264063B (hu) |
| MX (1) | MX2018015567A (hu) |
| MY (1) | MY197673A (hu) |
| NZ (1) | NZ749540A (hu) |
| PH (1) | PH12019500002B1 (hu) |
| PL (1) | PL3482760T3 (hu) |
| PT (1) | PT3482760T (hu) |
| RU (1) | RU2748731C2 (hu) |
| SG (1) | SG11201811591UA (hu) |
| TW (2) | TWI805255B (hu) |
| WO (1) | WO2018008711A1 (hu) |
| ZA (1) | ZA201900060B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102376248B1 (ko) * | 2015-01-09 | 2022-03-21 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
| EP3612517B1 (en) | 2017-04-18 | 2022-03-02 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| JP7159007B2 (ja) | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
| WO2019149286A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| CN112292128A (zh) * | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| DK3781550T3 (da) | 2018-04-17 | 2025-01-27 | Tempest Therapeutics Inc | Bicykliske carboxamider og fremgangsmåder til anvendelse deraf |
| JP7087892B2 (ja) | 2018-09-28 | 2022-06-21 | 株式会社島津製作所 | 真空度検出装置、及び電子線照射システム |
| EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| WO2020242773A1 (en) * | 2019-05-31 | 2020-12-03 | Clear Creek Bio, Inc. | Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| US20230040402A1 (en) * | 2019-12-25 | 2023-02-09 | Nippon Shinyaku Co., Ltd. | Antitumor drug for use in combination with immune checkpoint inhibitor |
| US20230102924A1 (en) * | 2020-03-10 | 2023-03-30 | Emory University | Methods of Treating Cancer Using Checkpoint Inhibitors in Combination with Purine Cleaving Enzymes |
| EP4245301A4 (en) * | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| WO2022247862A1 (zh) * | 2021-05-28 | 2022-12-01 | 南京明德新药研发有限公司 | 苯并螺杂环衍生物及其应用 |
| EP4404934A1 (en) * | 2021-09-21 | 2024-07-31 | Merck Sharp & Dohme LLC | Allosteric modulators of nicotinic acetylcholine receptors |
| WO2023198060A1 (zh) * | 2022-04-12 | 2023-10-19 | 正大天晴药业集团股份有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047497A2 (en) | 1998-03-13 | 1999-09-23 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| JP4929472B2 (ja) | 2000-08-22 | 2012-05-09 | 小野薬品工業株式会社 | カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| CN101284773A (zh) | 2001-08-09 | 2008-10-15 | 小野药品工业株式会社 | 羧酸衍生物及以它为活性成分的药剂 |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| MX2016015363A (es) * | 2014-05-23 | 2017-05-30 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de cancer. |
| KR102376248B1 (ko) | 2015-01-09 | 2022-03-21 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
-
2017
- 2017-07-06 NZ NZ749540A patent/NZ749540A/en unknown
- 2017-07-06 PH PH1/2019/500002A patent/PH12019500002B1/en unknown
- 2017-07-06 SG SG11201811591UA patent/SG11201811591UA/en unknown
- 2017-07-06 DK DK17824314.3T patent/DK3482760T3/da active
- 2017-07-06 US US16/315,063 patent/US11065226B2/en active Active
- 2017-07-06 CN CN201780042306.5A patent/CN109475520B/zh active Active
- 2017-07-06 EP EP17824314.3A patent/EP3482760B1/en active Active
- 2017-07-06 WO PCT/JP2017/024753 patent/WO2018008711A1/ja unknown
- 2017-07-06 TW TW111107751A patent/TWI805255B/zh active
- 2017-07-06 CA CA3029611A patent/CA3029611A1/en active Pending
- 2017-07-06 PL PL17824314T patent/PL3482760T3/pl unknown
- 2017-07-06 MY MYPI2018002961A patent/MY197673A/en unknown
- 2017-07-06 AU AU2017292522A patent/AU2017292522B2/en active Active
- 2017-07-06 PT PT178243143T patent/PT3482760T/pt unknown
- 2017-07-06 ES ES17824314T patent/ES2900306T3/es active Active
- 2017-07-06 KR KR1020197000093A patent/KR102473601B1/ko active IP Right Grant
- 2017-07-06 RU RU2018146479A patent/RU2748731C2/ru active
- 2017-07-06 MX MX2018015567A patent/MX2018015567A/es unknown
- 2017-07-06 HU HUE17824314A patent/HUE057799T2/hu unknown
- 2017-07-06 JP JP2017559144A patent/JP6323629B1/ja active Active
- 2017-07-06 TW TW106122678A patent/TWI795362B/zh active
-
2018
- 2018-03-20 JP JP2018053140A patent/JP7020218B2/ja active Active
-
2019
- 2019-01-02 IL IL264063A patent/IL264063B/en unknown
- 2019-01-04 ZA ZA2019/00060A patent/ZA201900060B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201900060B (en) | Combination comprising ep4 antagonist and immune checkpoint inhibitor | |
| IL286282A (en) | Use of palinabolin in combination with immune checkpoint inhibitors | |
| IL265922A (en) | tyk2 inhibitors and uses thereof | |
| HK1256796A1 (zh) | 二價溴結構域抑制劑及其用途 | |
| HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
| IL261586B (en) | A selective bromodomain inhibitor for bdii | |
| IL265274A (en) | Combined treatment of antibody and checkpoint inhibitor | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| GB201508074D0 (en) | People detection | |
| SG11201609248WA (en) | Nox inhibitor and nfκb inhibitor containing methoxyflavone | |
| HK1244486A1 (zh) | 三環dlk抑制劑及其用途 | |
| IL261584A (en) | Combination of cxcr4 antagonist and immune checkpoint inhibitor | |
| PL3543240T3 (pl) | Inhibitor urat1 i jego stosowanie | |
| PL3230318T3 (pl) | Kombinacje inhibitora immunologicznego punktu kontrolnego | |
| HK1254954A1 (zh) | Lpt-723和免疫檢查點抑制劑組合物及其治療方法 | |
| HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
| IL267238A (en) | The paranase inhibitors and their use | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| IL267243A (en) | The paranase inhibitors and their use | |
| ZA201807614B (en) | Bromodomain inhibitors | |
| GB201506127D0 (en) | Immune checkpoint inhibitor combinations | |
| IL247872A0 (en) | stat5 inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201505975D0 (en) | Inhibitors and their uses |